- Research Article
- 10.1016/j.jacc.2026.02.4417
26-CCC-10105-ACC FULMINANT GROWTH OF PRIMARY PERICARDIAL SYNOVIAL SARCOMA DESPITE PARTIAL RESECTION: A CASE REPORT
- Apr 01, 2026
- JACC
- Kuan-Yu Lin + 4 more +4
Publications from 2021 to 2026
Showing 10 of 1,101 papers
26-CCC-10105-ACC FULMINANT GROWTH OF PRIMARY PERICARDIAL SYNOVIAL SARCOMA DESPITE PARTIAL RESECTION: A CASE REPORT
26-CCC-19777-ACC BEYOND STEMI: MULTIMODALITY IMAGING LEADS TO TIMELY DIAGNOSIS OF CARDIAC SARCOIDOSIS
Assessing combined effects of RAI, GNRI, and Anemia on morbidity and mortality in elderly patients after subdural hematoma evacuation.
26-A-10262-ACC UTILITY OF MODIFIED SHOCK INDEX AND SOFA SCORE IN PREDICTING ADMISSION TO CARDIAC INTENSIVE CARE UNIT FOLLOWING RAPID RESPONSE TEAM ACTIVATION WITHIN 24 HOURS OF ADMISSION
Artificial Intelligence as a Prognostic Tool in Cardiac Amyloidosis: A Review.
Comparable Survival Does Not Imply Comparable Biology After Postcardiotomy Right Ventricular Failure.
P-1309. Comparative Treatment Outcomes of Non-Extended-Spectrum Beta-Lactamase (ESBL), Ceftriaxone Non-Susceptible, Enterobacterales Bacteremia with Piperacillin/Tazobactam, Cefepime, Carbapenem or Other Antibiotic Treatment
Abstract Background Treatment of ceftriaxone-resistant Enterobacterales is largely focused on ESBLs, with a carbapenem being the preferred treatment. A subset of ceftriaxone resistant Enterobacterales are non-ESBLs. These organisms test negative for both genotypic and phenotypic detection of ESBLs. There is a paucity of data surrounding optimal management of this unique infection. Methods This retrospective observational chart review evaluated adult patients admitted between January 2016 and November 2024 with a bacteremia caused by a non-ESBL, ceftriaxone-resistant, piperacillin/tazobactam (TZP)-sensitive, cefepime (FEP)-sensitive Escherichia coli, Klebsiella oxytoca, Proteus mirabilis, or Klebsiella pneumoniae. Exclusion criteria included bacteremias caused by the same organism within 6 months prior to the index blood culture, polymicrobial bacteremia, treatment without intent to cure, carbapenem resistance, antibiotics with Gram-negative bacterial coverage for another indication, pregnancy or lactation, or patients who expired within 48 hours of positive cultures. Patients were stratified into 3 groups depending on the administered targeted treatment (FEP or TZP vs. carbapenem vs. other). Results Of the 76 patients who were screened, 44 met the inclusion criteria. Four patients received a resistant cephalosporin for targeted treatment and were excluded from the analysis. There were 28 patients in the FEP or TZP group, 8 patients in the carbapenem group, and 4 patients in the other antibiotics group. The median age of the cohort was 77 years, most patients were female, and 30% of patients were in septic shock. The most common source of infection was genitourinary (63%). Thirty-day mortality was 3.8% in the FEP or TZP group, 14.3% in the carbapenem group, and 0% in the other antibiotic group (p=0.611). There was no significant difference in any of the secondary outcomes. Conclusion In this retrospective chart review study, there was no difference between carbapenem and non-carbapenem treatment for ceftriaxone-resistant, non-ESBL Enterobacterales bacteremia. Collaboration with other healthcare systems to increase sample size may help assess optimal treatment of these organisms. Disclosures All Authors: No reported disclosures
Read moreDe Novo and Recurrent Metabolic Dysfunction Associated Steatotic Liver Disease
From In‐Silico Optimized Microfabrication to Experimental Validation: Engineering a Tridimensional Epi‐Intraneural Interface
Abstract Vagus nerve stimulation shows promise for treating heart failure, epilepsy, diabetes, psychiatric disorders, but its clinical use is yet limited, possibly due to the poor spatial selectivity of cuff electrodes presently used. Existing intraneural electrodes offer higher selectivity but are invasive and complex to implant. An electrode with a unique feature of combining epineural and intraneural contacts was developed and optimized via in silico modeling for selective stimulation, rapid implantation, and minimal invasiveness. A tridimentional fabrication process integrating photolithography techniques with 2‐photon polymerization was engineered to create penetrating, narrow spikes on a flexible polyimide substrate. In vitro tests demonstrate mechanical robustness and enhance electrochemical properties thanks to customized titanium nitride coating. In vivo trials in rats and pigs showcase that the optimized design enables lower‐threshold stimulation with precise function targeting and fewer off‐target effects. This framework, including model‐driven design and novel fabrication process, enables precise tailoring of neural interfaces to diverse clinical targets, overcoming the selectivity–invasiveness trade‐off and advancing bioelectronic therapies toward closed‐loop control and chronic use.
Read moreRisk of Dementia in Immunocompromised and Non-immunocompromised Persons with COVID-19 Infection
Abstract COVID-19 infection is associated with an increased risk of developing dementia, particularly among older adults. We examined the impact of immune status on this risk using the COVID-19 Real World Data Infrastructure (DOI: 10.1093/0fid/ofaf021), a publicly available resource of 5.2 million unique deidentified patient records, linked with the NCI SEER registry. Two cohorts of patients were defined for the study period (12/1/2018-12/31/2024): COVID-19 Positive Persons (CPP) with positive SARS-CoV-2 NAAT and/or COVID-19 ICD-10 code. COVID-19 Negative Persons (CNP) had COVID-related information (including SARS-CoV-2 diagnostic or serologic testing and/or documented vaccination), but no positive NAAT or COVID-19 ICD-10 code. Patients < 65 years, with history of dementia or psychotropic medication use on or before index date (1/1/2020) were excluded. There were 225,852 CPP and 499,295 CNP eligible patients. Incidence of newly-diagnosed dementia among the CPP cohort was 25.6%, vs. 17.3% in CNP (Relative Risk [RR] 1.48; 95% CI: 1.46-1.49). Stratification by immunocompromised status (473,559 immunocompromised; 251,588 non-immunocompromised) showed no significant difference between RR for dementia associated with COVID-19 (RR = 1.48, 95% CI:1.46-1.50 and RR = 1.47, 95% CI: 1.45-1.50 respectively). These unadjusted analyses align with prior findings that COVID-19 infection in patients aged ≥65 years is associated with a greater risk of subsequent dementia diagnosis but suggest immunocompromised individuals have the same increased risk as the general population. Further analysis will examine timing of diagnoses, and relevance of covariates such as vaccination status and anti-viral medication use on dementia risk in CPP patients.
Read more